1. Pharmaceuticals and Drug Development

Sentynl Therapeutics Updates On Its NDA for CUTX-101

Solana Beach, CA – OCTOBER 1, 2025 – Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (“Zydus”), announced today that the U.S. Food and Drug…

Comments to: Sentynl Therapeutics Updates On Its NDA for CUTX-101

Login

Welcome to Life Science News!

"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.